echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Digestive System Information > Clin Gastroenterology H: Oral curcumin is no more effective than a placebo in preventing a recurrence of Crohn's disease

    Clin Gastroenterology H: Oral curcumin is no more effective than a placebo in preventing a recurrence of Crohn's disease

    • Last Update: 2020-07-10
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Background and objectivesthe recurrence of Crohn's disease (CD) after surgery is a major challengeCurcumin has an anti-inflammatory effect and promotes endoscopy in patients withulcerative colitisBased on endoscopy and clinical indicators, this study studied the efficacy of curcumin and placebo in patients treated with thiode inpreventionCD recurrencemethodsresearchers conducted a double-blind randomized controlled trial at eight referral centres in France between October 2014 and January 2018, in which 62 CD patients had a bowel ectomyThe patient satlifid thiopental (2.5 mg / kg) and was randomly divided into oral curcumin (3 g / day; n s 31) or the same placebo (n s 31) group for 6 months and then evaluated through a colonoscopyThe researchers also collected data on CD activity index, laboratory test results, and answers to the quality of life questionnaire over the six-month periodThe main endpoint was the recurrence of the CD at the 6th month of each group (Rutgeerts index score of si2)resultsin the 6th month, 18 patients (58%) who received curcumin and 21 patients receiving a placebo (68%) had postoperative recurrence (Rutgeerts index score of .i2) (P .60)Patients receiving curcumin (55%) had significantly higher rates of severe CD recurrence (Rutgeerts index of .i3) than those receiving a placebo (26%)We observed clinical recurrence of CDs in patients who received a placebo at 6 months and curcumin in 30% of patients (CD activity index score s.150) (P .80) The difference in quality of life scores for the sixth month between the groups was not significant (P - .80) Six percent of patients who received a placebo had severe adverse events, and 16 percent of patients receiving curcumin had severe adverse events (P.42) Conclusion
    this study found that curcumin was no more effective than placebo in preventing CD recurrence There was no significant difference between quality of life or severe adverse events between the two groups
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.